| Entry |
|
|---|
| Name |
Rivastigmine (JAN/USP/INN);
Exelon (TN);
Prometax (TN) |
|---|
| Product |
|
|---|
| Generic |
RIVASTIGMINE (Amneal Pharmaceuticals LLC), RIVASTIGMINE (Mylan Pharmaceuticals), RIVASTIGMINE (Northstar Rx LLC.), RIVASTIGMINE (Sandoz), RIVASTIGMINE (Zydus Lifesciences Limited), RIVASTIGMINE (Zydus Pharmaceuticals USA), RIVASTIGMINE TRANSDERMAL SYSTEM (Adhexpharma), RIVASTIGMINE TRANSDERMAL SYSTEM (Alvogen), RIVASTIGMINE TRANSDERMAL SYSTEM (Breckenridge Pharmaceutical), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack), RIVASTIGMINE TRANSDERMAL SYSTEM (Bryant Ranch Prepack) |
|---|
| Formula |
C14H22N2O2
|
|---|
| Exact mass |
250.1681
|
|---|
| Mol weight |
250.3367
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG01594 Butyrylcholinesterase inhibitor
DG01968 Antidementia agent
|
|---|
| Remark |
| Therapeutic category: | 1190 |
| Product (DG00984): | D03822<JP/US> D02558<US> |
|
|---|
| Efficacy |
Dementia therapeutic agent, Acetylcholinesterase inhibitor |
|---|
| Disease |
Alzheimer's disease [DS: H00056] |
|---|
| Comment |
Physostigmine derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07056 | Agents for Alzheimer-type dementia |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06D ANTI-DEMENTIA DRUGS
N06DA Anticholinesterases
N06DA03 Rivastigmine
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antidementia Agents
Cholinesterase Inhibitors
Rivastigmine
D03822 Rivastigmine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D03822 Rivastigmine (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00984 Rivastigmine
D03822 Rivastigmine
DG01594 Butyrylcholinesterase inhibitor
DG00984 Rivastigmine
D03822 Rivastigmine
DG01968 Antidementia agent
DG00984 Rivastigmine
D03822 Rivastigmine
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01968 Antidementia agent
D03822 Rivastigmine
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Carboxylic-ester hydrolases
ACHE
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
BCHE
D03822 Rivastigmine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03822
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03822
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01595 Cholinesterase inhibitor
DG01593 Acetylcholinesterase inhibitor
DG00984 Rivastigmine
DG01594 Butyrylcholinesterase inhibitor
DG00984 Rivastigmine
DG01968 Antidementia agent
DG00984 Rivastigmine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 18
1 C8y C 33.4600 -18.9700
2 C8x C 34.6500 -18.2700
3 C8x C 33.4600 -20.3700
4 O7a O 32.2000 -18.2700
5 C8y C 35.8400 -18.9700
6 C8x C 34.6500 -21.0700
7 C7a C 31.0100 -18.9700
8 C8x C 35.8400 -20.3700
9 N1c N 29.8200 -18.2700
10 O6a O 31.0100 -20.3700
11 C1a C 28.5600 -18.9700
12 C1c C 37.1000 -18.2700
13 N1c N 38.2900 -18.9700
14 C1a C 37.1000 -16.8700
15 C1a C 38.2900 -20.3700
16 C1a C 39.4800 -18.2700
17 C1b C 29.8200 -16.8700
18 C1a C 31.0800 -16.1700
BOND 18
1 5 8 2
2 7 9 1
3 7 10 2
4 9 11 1
5 6 8 1
6 5 12 1
7 1 2 2
8 12 13 1
9 1 3 1
10 12 14 1 #Down
11 1 4 1
12 13 15 1
13 2 5 1
14 13 16 1
15 3 6 2
16 9 17 1
17 4 7 1
18 17 18 1
|
|---|
